Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on developing innovative medicines targeting microRNAs, has announced its participation in two upcoming healthcare investment conferences. The company will be presenting at the Wells Fargo Healthcare Conference on September 4, 2024, at 2:15 p.m. ET, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 10:00 a.m. ET.
Both presentations will be available as live events and replays through the investor relations section of Regulus Therapeutics' website. The recordings will be archived for 90 days following each presentation date.
Regulus Therapeutics Inc. (Nasdaq: RGLS), una compagnia biofarmaceutica focalizzata nello sviluppo di medicinali innovativi che mirano ai microRNA, ha annunciato la sua partecipazione a due prossime conferenze di investimento nel settore sanitario. L'azienda presenterà alla Wells Fargo Healthcare Conference il 4 settembre 2024, alle 14:15 ET, e alla H.C. Wainwright 26th Annual Global Investment Conference il 9 settembre 2024, alle 10:00 ET.
Entrambe le presentazioni saranno disponibili come eventi dal vivo e in replica nella sezione dedicata alle relazioni con gli investitori del sito web di Regulus Therapeutics. Le registrazioni saranno archiviate per 90 giorni dopo la data di ciascuna presentazione.
Regulus Therapeutics Inc. (Nasdaq: RGLS), una compañía biofarmacéutica enfocada en desarrollar medicamentos innovadores que apuntan a los microARN, ha anunciado su participación en dos próximas conferencias de inversión en el sector salud. La compañía presentará en la Wells Fargo Healthcare Conference el 4 de septiembre de 2024, a las 14:15 ET, y en la H.C. Wainwright 26th Annual Global Investment Conference el 9 de septiembre de 2024, a las 10:00 ET.
Ambas presentaciones estarán disponibles como eventos en vivo y grabaciones a través de la sección de relaciones con inversores del sitio web de Regulus Therapeutics. Las grabaciones se archivarán durante 90 días posteriores a la fecha de cada presentación.
레귤루스 테라퓨틱스 Inc. (Nasdaq: RGLS), 마이크로RNA를 타겟으로 혁신적인 의약품 개발에 집중하는 바이오 제약 회사가 두 개의 다가오는 헬스케어 투자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 2024년 9월 4일 오후 2:15 ET에 웰스 파고 헬스케어 컨퍼런스에서 발표하며, 2024년 9월 9일 오전 10:00 ET에는 H.C. 웨인라이트 26차 연례 글로벌 투자 컨퍼런스에서 발표할 예정입니다.
두 발표는 라이브 이벤트와 재생으로 레귤루스 테라퓨틱스의 투자자 관계 섹션에서 제공될 것입니다. 녹음은 각 발표일로부터 90일간 보관됩니다.
Regulus Therapeutics Inc. (Nasdaq: RGLS), une entreprise bio-pharmaceutique axée sur le développement de médicaments innovants ciblant les microARN, a annoncé sa participation à deux prochaines conférences d'investissement dans le secteur de la santé. L'entreprise présentera lors de la Wells Fargo Healthcare Conference le 4 septembre 2024, à 14 h 15 ET, et à la H.C. Wainwright 26th Annual Global Investment Conference le 9 septembre 2024, à 10 h 00 ET.
Les deux présentations seront disponibles en tant qu'événements en direct et en rediffusion via la section relations investisseurs du site web de Regulus Therapeutics. Les enregistrements seront archivés pendant 90 jours après chaque date de présentation.
Regulus Therapeutics Inc. (Nasdaq: RGLS), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Arzneimittel zur gezielten Ansprache von Mikro-RNAs konzentriert, hat die Teilnahme an zwei bevorstehenden Investitionskonferenzen im Gesundheitswesen bekannt gegeben. Das Unternehmen wird am 4. September 2024 um 14:15 Uhr ET auf der Wells Fargo Healthcare Conference präsentieren und am 9. September 2024 um 10:00 Uhr ET auf der H.C. Wainwright 26th Annual Global Investment Conference.
Beide Präsentationen werden als Live-Events und als Wiederholungen über den Bereich für Investor Relations auf der Website von Regulus Therapeutics verfügbar sein. Die Aufzeichnungen werden für 90 Tage nach dem Datum jeder Präsentation archiviert.
- Participation in two major healthcare investment conferences
- Opportunity to present company updates to potential investors
- None.
- Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m. ET
The live events and replays of the presentations will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program and preclinical pipeline, the potential that RGLS8429 may be eligible for an Accelerated Approval pathway, potentially achieving therapeutic efficacy and clinical translation for patients, the expected timing for reporting interim or topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, that preliminary or topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and may not be indicative of future results, the FDA has not designated RGLS8429 for an Accelerated Approval pathway and such designation may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that RGLS8429 will receive marketing approval, the risk that preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, the risk that additional toxicology data may be negative, and risks related to our ability to successfully secure and deploy capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' quarterly report on Form 10-Q available on the Company's website or at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-302232255.html
SOURCE Regulus Therapeutics Inc.
FAQ
When is Regulus Therapeutics (RGLS) presenting at the Wells Fargo Healthcare Conference?
What time is Regulus Therapeutics (RGLS) scheduled for the H.C. Wainwright Global Investment Conference?
Where can investors access the presentations by Regulus Therapeutics (RGLS)?
How long will the Regulus Therapeutics (RGLS) conference presentations be available for replay?
